Trial Profile
Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2015
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinsonian disorders
- Focus Therapeutic Use
- 29 Nov 2015 New trial record